Pharmacists in Perry Hall, Maryland


13 Pharmacists found in Perry Hall
male pharmacist

Charles Imwold


Pharmacist
9504 Amberleigh Ln Unit Q, Perry Hall, MD 21128
410-302-7979    

female pharmacist

Crystal Dixon-baskerville, PHARMD


Pharmacist
9400 Scott Moore Way, Perry Hall, MD 21128
410-529-3980    

female pharmacist

Esther Zhi Liu, PHARMD


Pharmacist
5203 Scenic Dr, Perry Hall, MD 21128
443-552-4760    



female pharmacist

Hye Jin Lim, PHARM D


Pharmacist
9820 Belair Rd, Perry Hall, MD 21128
410-529-1460     410-529-1702

female pharmacist

Indira P Rallapalli, RPH


Pharmacist
9645 Belair Road, Perry Hall, MD 21128
410-256-6423     410-256-3765

female pharmacist

Kimberly Sgambati, PHARMD


Pharmacist
9400 Scott Moore Way, Perry Hall, MD 21128
410-529-3980     410-529-5992

female pharmacist

Laura Jago, PHARM D


Pharmacist
9820 Belair Rd, Perry Hall, MD 21128
410-529-1460     410-529-1702

male pharmacist

Dr. Newtin Nde Ndingwan, PHARMD


Pharmacist
9820 Belair Rd, Perry Hall, MD 21128
410-526-1460    

female pharmacist

Rachel Niloufar Habibi, PHARMD


Pharmacist
9516 Cross Rd, Perry Hall, MD 21128
804-243-9247    

male pharmacist

Dr. Sapan K Patel, PHARM.D.


Pharmacist
9820 Belair Rd, Perry Hall, MD 21128
410-529-1460    

male pharmacist

Dr. Tameem Ali Mousa, PHARMD


Pharmacist
9125 Rexis Ave, Perry Hall, MD 21128
443-857-5570    

female pharmacist

Uchechukwu Igwilo


Pharmacist
5016 Dorothy Field Rd, Perry Hall, MD 21128
410-804-8227    

male pharmacist

Visesh Velagapudi


Pharmacist
4405 Augusta Way, Perry Hall, MD 21128
410-900-4950    


Type of Pharmacists:
Psychiatric Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing care of patients with psychiatric illness by assessing and monitoring patients, recognizing drug-induced problems, and recommending appropriate treatment plans.
Oncology Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.